Payment overview · 2025
General Payments
$4,069.53
199 reported records · 22 companies
Healthcare provider profile · identity verified
Amy Trinh
Allopathic & Osteopathic Physicians|Family Medicine · LANSING, MI · NPI 1659869378
Verified facts
What the public records show
CMS Open Payments records show Amy Trinh received $4,069.53 in general payments during 2025 across 199 reported records.
ABBVIE INC. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tremfya.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tremfya by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 4976 records involving 2737 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tremfya by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $921.20 | 22.6% | 52 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $585.18 | 14.4% | 35 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $459.77 | 11.3% | 20 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $400.34 | 9.8% | 39 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $305.51 | 7.5% | 14 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $301.37 | 7.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $213.61 | 5.2% | 11 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $154.74 | 3.8% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.11 | 3.4% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $114.66 | 2.8% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.80 | 2.5% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $63.54 | 1.6% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $63.14 | 1.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.65 | 1.2% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $47.21 | 1.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.64 | 1.0% | 2 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $23.32 | 0.6% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $22.92 | 0.6% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $17.08 | 0.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.51 | 0.4% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $16.25 | 0.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $13.98 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,906.86 | 196 |
| Education | $162.67 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $760.93 | 49 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $555.08 | 41 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $424.28 | 18 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $301.37 | 2 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $280.45 | 13 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $255.36 | 37 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $254.50 | 11 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $213.61 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $167.94 | 13 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $130.71 | 10 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $100.80 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $92.96 | 6 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $69.78 | 5 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $63.14 | 3 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $43.11 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| GELSYN-3 Normalized: gelsyn 3 |
Device | Bioventus LLC | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 4976 supporting records · 2737 recipient NPIs · example record 1174147664 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 206 | 68 |
| Methotrexate | Methotrexate Sodium | 130 | 44 |
| Leflunomide | Leflunomide | 120 | 35 |
| Prednisone | Prednisone | 86 | 32 |
| Gabapentin | Gabapentin | 68 | 19 |
| Tramadol Hcl | Tramadol Hcl | 67 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 16 |
| Meloxicam | Meloxicam | 56 | 19 |
| Colchicine | Colchicine | 35 | suppressed |
| Humira(Cf) Pen | Adalimumab | 34 | suppressed |
| Sulfasalazine | Sulfasalazine | 34 | 15 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 32 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | 11 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Azathioprine | Azathioprine | 23 | suppressed |
| Enbrel Sureclick | Etanercept | 18 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Benlysta | Belimumab | 13 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Tremfya | Guselkumab | 12 | suppressed |
| Cosentyx Sensoready Pen | Secukinumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,069.53 · 199 records | ABBVIE INC. | Bimzelx, COSENTYX, CRYSVITA, ENBREL, EVENITY, GELSYN-3, HADLIMA, KEVZARA, KRYSTEXXA, OFEV, ORENCIA, OTEZLA, PEMGARDA, PROLIA, PURIFIED CORTROPHIN GEL, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, SPEVIGO, STRENSIQ, TALTZ, TAVNEOS, TERIPARATIDE, TREMFYA, Tymlos, VOQUEZNA, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tremfya play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error